Nivolumab is a humanized monoclonal antibody targeting PD-1, utilized for its anti-tumor activity in research on melanoma, non-small cell lung cancer, and renal cell carcinoma. It is widely applied in both in vitro assays and in vivo models to investigate immune checkpoint blockade mechanisms and therapeutic efficacy.
Concentration:
10.2 mg/mL
Molecular Weight:
146 kDa
Purity:
98.00% (May vary between batches)
CAS Number:
[946414-94-4]
Target:
PD-1/PD-L1
* VAT and and shipping costs not included. Errors and price changes excepted